ClinicalTrials.gg
CompletedNCT04807400SPIRITUpdated Oct 9, 2024Results posted

Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support

A Phase 3 interventional study of Inclisiran and Behavioural Support in Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents and Elevated Low Density Lipoprotein Cholesterol, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
892
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing inclisiran in Atherosclerosis — 3 open to participants now, 7 under way, 4 of them phase 3. inclisiran · Atherosclerosis.

Enrollment
4th of 16
892 · median 401
Started
2021
with 3 others
Phase 3
8 of 16
1 open now
Registered
5th of 16
by date
Lead sponsor
9 of 16
Novartis Pharmaceuticals

Among the 16 studies testing inclisiran in Atherosclerosis, this one is the 4th largest by enrollment, is one of 4 that started in 2021, is one of 8 in phase 3, and was the 5th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

3 of the 16 studies testing inclisiran in Atherosclerosis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing inclisiran in Atherosclerosis, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the implementation of inclisiran in a regional primary care setting in the UK

Inclisiran, also known as KJX839, is a medication made to reduce the level of "bad" cholesterol (LDL-cholesterol) in the blood. Inclisiran works in a way that makes the liver produce less of a substance called 'PCSK9'. PCSK9 reduces the ability of the liver to remove LDL-cholesterol from the blood. By lowering the production of PCSK9, Inclisiran leads to more LDL-cholesterol being removed by the liver from the blood, thereby reducing LDL-cholesterol overall.

Read the detailed description

A phase IIIb, multicenter, randomized controlled study to evaluate the implementation, preference, and utility for administration of inclisiran sodium in participants on established lipid lowering medication or, have been recommended lipid lowering therapy by their healthcare provider but are unable to tolerate treatment, with elevated low density lipoprotein cholesterol (LDL-C) in a primary care population. This study was an implementation research study that utilized implementation science methodology and use of the electronic medical record (EMR).

Using implementation science methodology, the study intended to assess the effect of 9 months treatment with inclisiran with/without behavioural support, compared to standard of care + behavioural support, on LDL-C reduction, total lipid profile, assessments of patient and healthcare professional (HCP) satisfaction, health-care resource utilization and healthcare service process evaluation.

The primary focus of this study was implementation and 'transactability' - how to organize, deliver and maintain an innovative treatment for Atherosclerotic Cardiovascular Disease (ASCVD) in a primary care setting in a sustainable way.

Patients taking part in the study were randomised to one of three groups:

  • Control + BS: Participants continued to receive their background lipid lowering therapy plus behavioural support. Subjects in treatment group 1 were referred to as the control group in this study
  • Inclisiran: Participants continue to receive their background lipid lowering therapy, plus inclisiran for injection (delivered in an injection-only model).
  • Inclisiran + BS: Participants continued to receive their background lipid lowering therapy, plus inclisiran for injection, plus behavioural support.

Participants who were randomized to Inclisiran or Inclisiran + BS received one injection of inclisiran on Day 1 and a second injection of inclisiran on Day 90.

Participants in Control + BS and Inclisiran + BS received a monthly telephone call from a health advisor, providing support to enable participants to make positive behaviour changes to reduce their cardiovascular risk.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease
  • Atherosclerotic Cardiovascular Disease Risk Equivelents
  • Elevated Low Density Lipoprotein Cholesterol

Browse trials for

Keywords

  • Atherosclerotic Cardiovascular Disease
  • Atherosclerotic Cardiovascular Disease Risk Equivalents
  • Elevated Low Density Lipoprotein Cholesterol
  • ASCVD
  • LDL-C
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed had to be obtained prior to participation in the study.
  2. Patients on established lipid lowering medication or, have been recommended lipid lowering therapy by their health care provider but were unable to tolerate treatment.
  3. A total cholesterol measurement at screening that was ≥4 mmol/L [approximately 160 mg/dL].
  4. Participants on lipid-lowering therapies had to be on a stable dose for ≥30 days before screening with no planned medication or dose change.

Exclusion criteria

Exclusion Criteria:

  1. Medical or surgical history that might limit the individual's ability to take study treatments for the duration of the study and/or put the participant at significant risk .
  2. Current or planned renal dialysis or transplantation.
  3. Acute coronary syndrome or stroke less than 4 weeks before the screening visit.
  4. Coronary revascularization procedure planned within the next 6 months.
  5. Women of , unless they agree to abstinence or, if sexually active, agree to the use of effective methods of during the study.
  6. Women who are pregnant or breast-feeding.
  7. Previous, current or planned treatment with a monoclonal antibody targeting PCSK9, or with a drug known to be with inclisiran.
  8. Previous exposure to inclisiran or participation in a randomised study of inclisiran.
  9. Current or previous participation in a clinical study with an unlicensed drug or device within 30 days or five half-lives of the screening visit, whichever is longer.
  10. Participants who planed to move away from the geographical area where the study is being conducted during the study period.
  11. A triglyceride measurement at screening that is greater than or equal to 4.52 mmol/L
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
892 participants (actual)

Study arms

  • Active comparator
    Control+ BS

    Participants continued to receive their background lipid lowering therapy plus behavioural support (BS).

    Behavioral: Behavioural Support · Drug: Background lipid lowering therapy

  • Experimental
    Inclisiran

    Participants continue to receive their background lipid lowering therapy, plus inclisiran for injection (delivered in an injection-only model).

    Drug: Inclisiran · Drug: Background lipid lowering therapy

  • Experimental
    Inclisiran + BS

    Participants continued to receive their background lipid lowering therapy, plus inclisiran for injection, plus behavioural support.

    Drug: Inclisiran · Behavioral: Behavioural Support · Drug: Background lipid lowering therapy

Interventions

  • Inclisiran Sodium 300mg on Day 1 and Day 90 by subcutaneous injection

  • BehavioralBehavioural Support

    Regular telephone based behavioural support programme delivered throughout the study period, as measured by point of care testing device.

  • DrugBackground lipid lowering therapy

    lipid-lowering therapy (such as a statin and/or ezetimibe) as background therapy

06

What researchers measure

Primary outcomes

  1. Percentage Change in LDL-C From Baseline to Day 270

    Change in Low Density Lipoprotein Cholesterol (LDL-C) after 270 days of treatment in adults on established lipid lowering medication or who have been recommended lipid lowering therapy by their health care provider but are unable to tolerate treatment, regardless of treatment discontinuation for any reason and regardless of unforeseen change in the concomitant lipid lowering therapy. Multiple imputation is used to impute missing data using a washout model.

    Time frame: Baseline, Day 270

Secondary outcomes

  1. Number of Participants Interviewed for CFIR Analysis.

    To identify the need to support the implementation of inclisiran in the real world, a framework was drawn known as the Consolidated Framework for Implementation Research (CFIR). Patients who received inclisiran were interviewed to understand their experience with the program and to obtain a comprehensive understanding, with or without behavioural support. These patients were interviewed on various aspects of their experience related to their high cholesterol management, trial participation, inclisiran injections, attending appointments, and if applicable their experience with the behavioural support programme. These interviews were not set up in a way that allow numerical analysis. The process evaluation was conducted by Manchester University.

    Time frame: Day 270

  2. Patient Reported Outcomes: CSQ-8 Total Score After Treatment

    The Client Satisfaction Questionnaire (CSQ)-8 is the standard self-administered CSQ scale containing 8 items that comprise the measurement of satisfaction with services and measurement of improvement of capacity to cope and change adaptively. Items include questions enquiring about respondents' opinions and conclusions about services they have received or are currently receiving. Response options differ from item to item, but all are based on a four-point scale. For the CSQ-8 version, scores range from 8 to 32, with higher values indicating higher satisfaction.

    Time frame: Day 90

  3. Patient Reported Outcomes: CSQ-8 Total Score Between Inclisiran Arms

    The CSQ-8 is the standard self-administered CSQ scale containing 8 items that comprise the measurement of satisfaction with services and measurement of improvement of capacity to cope and change adaptively. Items include questions enquiring about respondents' opinions and conclusions about services they have received or are currently receiving. Response options differ from item to item, but all are based on a four-point scale. For the CSQ-8 version, scores range from 8 to 32, with higher values indicating higher satisfaction. This secondary outcome only analysed data of the two Inclisiran arms, by considering the Inclisiran only arm as the control group. The standard error for Least Square Mean could change because dropping a treatment arm affects the estimation of treatment effects and the variability of data.

    Time frame: Day 90

  4. Change From Baseline to Day 90 in Total PAM Score

    The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements relating to patients beliefs about health care, confidence in their management of health related tasks, and self-assessed knowledge of their condition. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. A standardised spreadsheet in excel is used to score the PAM. Responses are used to generate a continuous score from 0 to 100 where higher scores indicate that the patient is more activated.

    Time frame: Baseline, Day 90

  5. Change From Baseline to Day 90 in Total PAM Score Between Inclisiran Arms

    The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. Responses are used to generate a continuous score from 0 to 100 where higher scores indicate that the patient is more activated. This outcome only analysed data of the two inclisiran arms, by considering the Inclisiran only arm as the control group. In an ANCOVA model, the Least Squares Means and corresponding Standard Error could change because the removal of a treatment group affects the estimation of the treatment effects and the adjustment for the covariate(s).

    Time frame: Baseline, Day 90

  6. Measures of Adherence to Cardiovascular Disease Self-management Using the Validated Patient Activation Measure (PAM) Questionnaire.

    The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements relating to patients beliefs about health care, confidence in their management of health related tasks, and self-assessed knowledge of their condition. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. Responses are used to generate a continuous score from 0 to 100. The continuous PAM scores are then categorised into 4 levels: Level 1 - disengaged and overwhelmed; Level 2 - become aware but still struggling; Level 3 - taking action; Level 4 - maintaining behaviors and pushing further.

    Time frame: Baseline, Day 90

07

Results

Posted Mar 25, 2024

Participant flow

The study was conducted at 17 primary care centres with a network of research ready General Practitioners across Greater Manchester, United Kingdom.

Participant flow — Overall Study
MilestoneInclisiranInclisiran + BSControl+ BS
Started298297297
Full analysis set297297297
Safety set273281290
Completed248252234
Not completed504563
Withdrew: Adverse event233
Withdrew: Death200
Withdrew: Lost to follow-up866
Withdrew: Non-compliance with study drug041
Withdrew: Participant decision201926
Withdrew: Physician decision010
Withdrew: Protocol violation437
Withdrew: Withdrawal by subject13920
Withdrew: Mis-randomized100

Outcome measures

PrimaryPercentage Change in LDL-C From Baseline to Day 270

Change in Low Density Lipoprotein Cholesterol (LDL-C) after 270 days of treatment in adults on established lipid lowering medication or who have been recommended lipid lowering therapy by their health care provider but are unable to tolerate treatment, regardless of treatment discontinuation for any reason and regardless of unforeseen change in the concomitant lipid lowering therapy. Multiple imputation is used to impute missing data using a washout model.

Time frame:
Baseline, Day 270
Reported as:
Least squares mean · percent change from baseline in LDL-C
Percentage Change in LDL-C From Baseline to Day 270
percent change from baseline in LDL-CInclisiranInclisiran + BSControl+ BS
Percentage Change in LDL-C From Baseline to Day 270-37.3 ± 2.29-37.6 ± 2.33-5.4 ± 2.34
Statistical analysis
  • Inclisiran vs Control+ BS · ANCOVA · p = <0.001 (p-values are adjusted using Holm's procedure.) · Least squares mean: -31.8 · 95% CI -37.91 to -25.77
  • Inclisiran + BS vs Control+ BS · ANCOVA · p = <0.001 (p-values are adjusted using Holm's procedure.) · Least squares mean: -32.1 · 95% CI -38.35 to -25.94
SecondaryNumber of Participants Interviewed for CFIR Analysis.

To identify the need to support the implementation of inclisiran in the real world, a framework was drawn known as the Consolidated Framework for Implementation Research (CFIR). Patients who received inclisiran were interviewed to understand their experience with the program and to obtain a comprehensive understanding, with or without behavioural support. These patients were interviewed on various aspects of their experience related to their high cholesterol management, trial participation, inclisiran injections, attending appointments, and if applicable their experience with the behavioural support programme. These interviews were not set up in a way that allow numerical analysis. The process evaluation was conducted by Manchester University.

Time frame:
Day 270
Reported as:
Count of participants · Participants
Number of Participants Interviewed for CFIR Analysis.
ParticipantsInclisiranInclisiran + BS
Number of Participants Interviewed for CFIR Analysis.2828
SecondaryPatient Reported Outcomes: CSQ-8 Total Score After Treatment

The Client Satisfaction Questionnaire (CSQ)-8 is the standard self-administered CSQ scale containing 8 items that comprise the measurement of satisfaction with services and measurement of improvement of capacity to cope and change adaptively. Items include questions enquiring about respondents' opinions and conclusions about services they have received or are currently receiving. Response options differ from item to item, but all are based on a four-point scale. For the CSQ-8 version, scores range from 8 to 32, with higher values indicating higher satisfaction.

Time frame:
Day 90
Reported as:
Least squares mean · score on a scale
Patient Reported Outcomes: CSQ-8 Total Score After Treatment
score on a scaleInclisiranInclisiran + BSControl+ BS
Patient Reported Outcomes: CSQ-8 Total Score After Treatment30.1 ± 0.2430.1 ± 0.2428.7 ± 0.30
Statistical analysis
  • Inclisiran vs Control+ BS · ANOVA · p = <0.001 · Least-squares mean: 1.4 · 95% CI 0.62 to 2.13
  • Inclisiran + BS vs Control+ BS · ANOVA · p = <0.001 · Least-squares mean: 1.3 · 95% CI 0.60 to 2.10
SecondaryPatient Reported Outcomes: CSQ-8 Total Score Between Inclisiran Arms

The CSQ-8 is the standard self-administered CSQ scale containing 8 items that comprise the measurement of satisfaction with services and measurement of improvement of capacity to cope and change adaptively. Items include questions enquiring about respondents' opinions and conclusions about services they have received or are currently receiving. Response options differ from item to item, but all are based on a four-point scale. For the CSQ-8 version, scores range from 8 to 32, with higher values indicating higher satisfaction. This secondary outcome only analysed data of the two Inclisiran arms, by considering the Inclisiran only arm as the control group. The standard error for Least Square Mean could change because dropping a treatment arm affects the estimation of treatment effects and the variability of data.

Time frame:
Day 90
Reported as:
Least squares mean · score on a scale
Patient Reported Outcomes: CSQ-8 Total Score Between Inclisiran Arms
score on a scaleInclisiran + BSInclisiran
Patient Reported Outcomes: CSQ-8 Total Score Between Inclisiran Arms30.1 ± 0.2330.1 ± 0.23
Statistical analysis
  • Inclisiran + BS vs Inclisiran · ANOVA · p = 0.9347 · Least-squares mean: -0.03 · 95% CI -0.67 to 0.61
SecondaryChange From Baseline to Day 90 in Total PAM Score

The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements relating to patients beliefs about health care, confidence in their management of health related tasks, and self-assessed knowledge of their condition. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. A standardised spreadsheet in excel is used to score the PAM. Responses are used to generate a continuous score from 0 to 100 where higher scores indicate that the patient is more activated.

Time frame:
Baseline, Day 90
Reported as:
Least squares mean · score on a scale
Change From Baseline to Day 90 in Total PAM Score
score on a scaleInclisiranInclisiran + BSControl+ BS
Change From Baseline to Day 90 in Total PAM Score2.4 ± 1.182.7 ± 1.141.4 ± 2.01
Statistical analysis
  • Inclisiran vs Control+ BS · ANCOVA · p = 0.6759 · Least-squares mean: 1.0 · 95% CI -3.62 to 5.58
  • Inclisiran + BS vs Control+ BS · ANCOVA · p = 0.5756 · Least-squares mean: 1.3 · 95% CI -3.25 to 5.84
SecondaryChange From Baseline to Day 90 in Total PAM Score Between Inclisiran Arms

The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. Responses are used to generate a continuous score from 0 to 100 where higher scores indicate that the patient is more activated. This outcome only analysed data of the two inclisiran arms, by considering the Inclisiran only arm as the control group. In an ANCOVA model, the Least Squares Means and corresponding Standard Error could change because the removal of a treatment group affects the estimation of the treatment effects and the adjustment for the covariate(s).

Time frame:
Baseline, Day 90
Reported as:
Least squares mean · score on a scale
Change From Baseline to Day 90 in Total PAM Score Between Inclisiran Arms
score on a scaleInclisiran + BSInclisiran
Change From Baseline to Day 90 in Total PAM Score Between Inclisiran Arms2.6 ± 1.172.3 ± 1.21
Statistical analysis
  • Inclisiran + BS vs Inclisiran · ANCOVA · p = 0.8580 · Least-squares mean: 0.3 · 95% CI -3.02 to 3.62
SecondaryMeasures of Adherence to Cardiovascular Disease Self-management Using the Validated Patient Activation Measure (PAM) Questionnaire.

The Patient Activation Measure (PAM) questionnaire is a survey that assesses a person's underlying knowledge, skills and confidence integral to managing his or her own health and healthcare. This study used the 13-point PAM questionnaire, which consists of 13 statements relating to patients beliefs about health care, confidence in their management of health related tasks, and self-assessed knowledge of their condition. For each statement patients are required to say how much they either agree or disagree on a response scale of 1-5, where 1 represents "strongly disagree", 4 represents "strongly agree" and 5 indicates that the statement is "not applicable" to them. Responses are used to generate a continuous score from 0 to 100. The continuous PAM scores are then categorised into 4 levels: Level 1 - disengaged and overwhelmed; Level 2 - become aware but still struggling; Level 3 - taking action; Level 4 - maintaining behaviors and pushing further.

Time frame:
Baseline, Day 90
Reported as:
Count of participants · Participants
Measures of Adherence to Cardiovascular Disease Self-management Using the Validated Patient Activation Measure (PAM) Questionnaire.
ParticipantsInclisiranInclisiran + BSControl+ BS
Level 1 (Disengaged and overwhelmed) at Baseline13207
Level 2 (Become aware but still struggling) at Baseline475015
Level 3 (Taking action) at Baseline617536
Level 4 (Maintaining behaviors and pushing further) at Baseline484421
Missing PAM scores at baseline128108218
Level 1 (Disengaged and overwhelmed) at Day 90986
Level 2 (Become aware but still struggling) Day 90373823
Level 3 (Taking action) at Day 90636446
Level 4 (Maintaining behaviors and pushing further) at Day 90564733
Missing PAM scores at Day 90132140189

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study visit plus 30 days post treatment, up to a maximum duration of 300 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inclisiran2/273 (0.7%)24/273 (8.8%)3/273 (1.1%)
Inclisiran + BS0/281 (0%)36/281 (12.8%)2/281 (0.7%)
Control + BS0/290 (0%)28/290 (9.7%)0/290 (0%)
Total2/844 (0.2%)88/844 (10.4%)5/844 (0.6%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventInclisiranInclisiran + BSControl + BSTotal
Atrial fibrillationCardiac disorders2/2735/2810/2907/844
PneumoniaInfections and infestations4/2731/2811/2906/844
Type 2 diabetes mellitusMetabolism and nutrition disorders3/2731/2812/2906/844
Suicidal ideationPsychiatric disorders2/2730/2811/2903/844
Acute kidney injuryRenal and urinary disorders2/2732/2810/2904/844
DiverticulitisInfections and infestations0/2732/2810/2902/844
Urinary tract infectionInfections and infestations1/2732/2810/2903/844
UrosepsisInfections and infestations1/2732/2810/2903/844
Acute myocardial infarctionCardiac disorders1/2731/2812/2904/844
Iron deficiency anaemiaBlood and lymphatic system disorders1/2730/2810/2901/844
Most frequent other events
Most frequent other events
EventInclisiranInclisiran + BSControl + BSTotal
Injection site rashGeneral disorders1/2730/2810/2901/844
Back painMusculoskeletal and connective tissue disorders1/2730/2810/2901/844
Muscle spasmsMusculoskeletal and connective tissue disorders1/2730/2810/2901/844
Pain in extremityMusculoskeletal and connective tissue disorders1/2730/2810/2901/844
DizzinessNervous system disorders0/2731/2810/2901/844
RashSkin and subcutaneous tissue disorders0/2731/2810/2901/844

Baseline characteristics

Baseline Participants are based on the Full Analysis Set (FAS) population, as primary and secondary analysis are based on the FAS

Age, Continuous
Age, Continuous(Years)InclisiranInclisiran + BSControl+ BSTotal
Mean66.0 ± 9.2765.8 ± 9.7166.7 ± 9.4566.2 ± 9.47
Sex: Female, Male
Sex: Female, Male(Participants)InclisiranInclisiran + BSControl+ BSTotal
Female170174180524
Male127123117367
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)InclisiranInclisiran + BSControl+ BSTotal
Asian113923
Black1056
Mixed1315
White281289278848
Other3249
08

Study locations

17 sites
  • Novartis Investigative Site
    Sale, Cheshire M33 4BR, United Kingdom
  • Novartis Investigative Site
    Altrincham, Manchester WA14 1PF, United Kingdom
  • Novartis Investigative Site
    Davyhulme, Manchester M41 7WJ, United Kingdom
  • Novartis Investigative Site
    Didsbury, Manchester M20 6BA, United Kingdom
  • Novartis Investigative Site
    Northenden, Manchester M22 4DH, United Kingdom
  • Novartis Investigative Site
    Sale, Manchester M33 2TB, United Kingdom
  • Novartis Investigative Site
    Swinton, Manchester M27 8HP, United Kingdom
  • Novartis Investigative Site
    Wythenshawe, Manchester M22 0EP, United Kingdom
  • Novartis Investigative Site
    Wythenshawe, Manchester M22 5RX, United Kingdom
  • Novartis Investigative Site
    Chadderton, OL9 0LH, United Kingdom
  • Novartis Investigative Site
    Cheadle Hulme, SK8 5LL, United Kingdom
  • Novartis Investigative Site
    Greater Manchester, M24 4DZ, United Kingdom
  • Novartis Investigative Site
    Lancashire, OL6 6EW, United Kingdom
  • Novartis Investigative Site
    Manchester, M14 5NP, United Kingdom
  • Novartis Investigative Site
    Manchester, M14 6WP, United Kingdom
  • Novartis Investigative Site
    Manchester, M20 2RN, United Kingdom
  • Novartis Investigative Site
    Manchester, M33 2RH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jan 2023, 18 months.

Results were first posted in Mar 2024, 1 year 2 months after primary completion.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 18 months is below that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2021
First posted
Mar 19, 2021
StartActual
Jul 7, 2021
Primary completionActual
Jan 13, 2023
CompletionActual
Jan 13, 2023
Results first posted
Mar 25, 2024
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04807400
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Jul 7, 2021
Primary completion
Jan 13, 2023
Completion
Jan 13, 2023
Results posted
Mar 25, 2024
Last update
Oct 9, 2024

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion